From the Research
Annexin markers, particularly Annexin A5, play a crucial role in inhibiting diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling, as evidenced by a study published in 2014 1.
Importance of Annexin Markers in Lymphoma
The use of Annexin markers in lymphoma diagnosis and monitoring is well-established, with Annexin V being a valuable tool in detecting programmed cell death in lymphoma cells.
- Annexin V binds to phosphatidylserine, a membrane phospholipid that becomes exposed on the cell surface during early apoptosis.
- This marker is commonly used in flow cytometry assays to distinguish early apoptotic cells from late apoptotic or necrotic cells.
- In lymphoma management, Annexin V assays help evaluate treatment efficacy by measuring apoptosis induction following chemotherapy or radiation.
Recent Studies on Diffuse Large B-Cell Lymphoma
Recent studies have focused on the treatment and management of diffuse large B-cell lymphoma, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) being the standard treatment 2, 3, 4, 5.
- A study published in 2021 highlighted the importance of R-CHOP immunochemotherapy in curing over 60% of patients with diffuse large B-cell lymphoma 5.
- However, patients with treatment failure after R-CHOP often have a poor outcome, emphasizing the need for alternative therapeutic approaches.
- The role of Annexin A5 in inhibiting cell invasion and chemoresistance in diffuse large B-cell lymphoma cells has been explored, with results suggesting a potential therapeutic target 1.